Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Other Revenues: $507M in Q3 2026, up 12.9% from a year earlier.
Latest, Q3 2026
507
Period ended Sep 30, 2026
Change on a year earlier
+12.9%
449 in Q3 2025
History
17 quarters
Since Q3 2022
Sources
13
Documents cited below
Where the Q3 2026 figure comes from
“|| Total other revenues | 507 | 449 | 1 461 | 1 618”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K Note 3 & Form 20-F Note 3.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up other Revenues
Cite this data
StockData. (2026). Novartis Other Revenues ($M), quarterly Q3 2022–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/collab-other-revenues-total
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.